CN101675922A - 角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 - Google Patents
角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 Download PDFInfo
- Publication number
- CN101675922A CN101675922A CN200910167495A CN200910167495A CN101675922A CN 101675922 A CN101675922 A CN 101675922A CN 200910167495 A CN200910167495 A CN 200910167495A CN 200910167495 A CN200910167495 A CN 200910167495A CN 101675922 A CN101675922 A CN 101675922A
- Authority
- CN
- China
- Prior art keywords
- receptor
- pore
- parakeratosis
- antagonist
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011148 porous material Substances 0.000 claims abstract description 59
- 208000005775 Parakeratosis Diseases 0.000 claims abstract description 43
- 239000005557 antagonist Substances 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 239000003112 inhibitor Substances 0.000 claims abstract description 12
- 229930182847 D-glutamic acid Natural products 0.000 claims description 11
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 9
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 9
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 81
- 108020003175 receptors Proteins 0.000 abstract description 81
- 239000000556 agonist Substances 0.000 abstract description 36
- 239000000203 mixture Substances 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 21
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract description 10
- 102000018899 Glutamate Receptors Human genes 0.000 abstract description 9
- 108010027915 Glutamate Receptors Proteins 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 102000011714 Glycine Receptors Human genes 0.000 abstract description 6
- 108010076533 Glycine Receptors Proteins 0.000 abstract description 6
- 102000002294 Purinergic P2X Receptors Human genes 0.000 abstract description 5
- 108010000836 Purinergic P2X Receptors Proteins 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 230000002964 excitative effect Effects 0.000 abstract description 4
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 abstract 1
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 abstract 1
- 102100037601 P2X purinoceptor 4 Human genes 0.000 abstract 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 abstract 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 abstract 1
- 229940065734 gamma-aminobutyrate Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 210000003491 skin Anatomy 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 206010022998 Irritability Diseases 0.000 description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 20
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 19
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 18
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 18
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 18
- 239000005642 Oleic acid Substances 0.000 description 18
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 14
- 235000013599 spices Nutrition 0.000 description 14
- YJWBWQWUHVXPNC-AWEZNQCLSA-N Dicentrine Chemical compound CN([C@H]1CC=2C=C(C(=CC=2C2=C11)OC)OC)CCC1=CC1=C2OCO1 YJWBWQWUHVXPNC-AWEZNQCLSA-N 0.000 description 12
- -1 ascorbic acid glucosides Chemical class 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 9
- 238000005342 ion exchange Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000002374 sebum Anatomy 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 229940058015 1,3-butylene glycol Drugs 0.000 description 7
- 102000005915 GABA Receptors Human genes 0.000 description 7
- 108010005551 GABA Receptors Proteins 0.000 description 7
- KRVDMABBKYMBHG-UHFFFAOYSA-N Isoguvacine Chemical compound OC(=O)C1=CCNCC1 KRVDMABBKYMBHG-UHFFFAOYSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- DSFVPALDDWRTFF-DIBLVGDCSA-N TNP-ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O1)N2C=3N=CN=C(C=3N=C2)N)C21C([N+]([O-])=O)C=C([N+]([O-])=O)C=C2[N+]([O-])=O DSFVPALDDWRTFF-DIBLVGDCSA-N 0.000 description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 7
- 210000004927 skin cell Anatomy 0.000 description 7
- 229960005314 suramin Drugs 0.000 description 7
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 7
- YJWBWQWUHVXPNC-UHFFFAOYSA-N O-methyl-phanostenine Natural products C12=C3C=4C=C(OC)C(OC)=CC=4CC2N(C)CCC1=CC1=C3OCO1 YJWBWQWUHVXPNC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003780 keratinization Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- PNFZSRRRZNXSMF-UHFFFAOYSA-N 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid Chemical compound O=CC1=C(O)C(C)=NC(N=NC=2C(=CC(=CC=2)S(O)(=O)=O)S(O)(=O)=O)=C1COP(O)(O)=O PNFZSRRRZNXSMF-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000003855 balanced salt solution Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
- 229960002216 methylparaben Drugs 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000037332 pore function Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 3
- 229950004794 dizocilpine Drugs 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- QFBCQOXKGBYUSU-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;pyridine-3-carboxylate Chemical compound [O-]C(=O)C1=CC=CN=C1.CC(=O)OCC[N+](C)(C)C QFBCQOXKGBYUSU-UHFFFAOYSA-M 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- ZEBMMHUDQRRILP-WZSMAATHSA-N Condelphine Chemical compound CC(=O)O[C@@H]1[C@H]2[C@@H]3[C@@]4([C@@H]5C6)[C@@H](O)CC[C@@]5(COC)CN(CC)C4[C@H]6[C@@]2(O)C[C@H](OC)[C@H]1C3 ZEBMMHUDQRRILP-WZSMAATHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- BZQKPKLKOSTBMK-UHFFFAOYSA-N condelphine Natural products CC(=O)OC1C2C3C4(C5C6)C(OC(C)=O)CCC5(COC)CN(CC)C4C6C2(O)CC(OC)C1C3 BZQKPKLKOSTBMK-UHFFFAOYSA-N 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 2
- 229940093767 glabridin Drugs 0.000 description 2
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 2
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MYDMWESTDPJANS-ZCFIWIBFSA-N (2r)-2-amino-7-phosphonoheptanoic acid Chemical compound OC(=O)[C@H](N)CCCCCP(O)(O)=O MYDMWESTDPJANS-ZCFIWIBFSA-N 0.000 description 1
- CUVGUPIVTLGRGI-SSDOTTSWSA-N (2r)-4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-SSDOTTSWSA-N 0.000 description 1
- BWXCECYGGMGBHD-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;bromide Chemical compound [Br-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 BWXCECYGGMGBHD-GRTNUQQKSA-M 0.000 description 1
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- NDHNBHXAALUAAJ-UHFFFAOYSA-N 4,5-dimorpholin-4-yl-1h-pyridazin-6-one Chemical compound C1COCCN1C=1C(O)=NN=CC=1N1CCOCC1 NDHNBHXAALUAAJ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- UNDXPKDBFOOQFC-UHFFFAOYSA-N 4-[2-nitro-4-(trifluoromethyl)phenyl]morpholine Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1N1CCOCC1 UNDXPKDBFOOQFC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229940098788 GABA receptor antagonist Drugs 0.000 description 1
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 244000128206 Pyracantha coccinea Species 0.000 description 1
- 235000003105 Pyracantha coccinea Nutrition 0.000 description 1
- 241000736246 Pyrola Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BZQGBLOEMSHEKP-UHFFFAOYSA-N azane;cyclohexa-2,5-diene-1,4-dione Chemical compound N.O=C1C=CC(=O)C=C1 BZQGBLOEMSHEKP-UHFFFAOYSA-N 0.000 description 1
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000002431 glycine receptor agonist Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明的课题在于阐明毛孔明显的机理,提供一种具有缩小毛孔机能的物质,进一步提供一种发挥上述机能、改善毛孔明显症状的皮肤外用剂等的组合物。为解决课题而采取的方法为一种含有N-甲基-D-天冬氨酸等的谷氨酸受体、P2X受体等的ATP受体等兴奋性细胞受体的拮抗剂或C1-通道内置型荷包牡丹碱敏感性受体等的γ-氨基丁酸受体、甘氨酸受体等抑制性细胞受体的激动剂的角化不全抑制剂、毛孔缩小剂,进一步为含有上述兴奋性细胞受体的拮抗剂或上述抑制性细胞受体的激动剂的角化不全抑制用皮肤外用剂、毛孔缩小用皮肤外用剂。通过本发明,能够发挥抑制角化不全、毛孔缩小的机能,维持毛孔不明显的健康肌肤状态。
Description
本发明申请是PCT专利申请PCT/JP03/06467,申请日为2003年5月23日发明名称为“角化不全抑制剂、毛孔缩小剂以及皮肤外用剂”的发明专利申请的分案申请,母案进入中国的申请号为03812309.6。
技术领域
本发明涉及一种对由皮脂引起的角化不全进行抑制的角化不全抑制剂。尤其涉及对由毛孔周围的皮脂中的刺激成分引起的角化不全进行抑制、使得毛孔周围的皮肤保持正常、对毛孔的圆锥状结构的明显化进行抑制的毛孔缩小剂。进一步涉及含有能发挥这些机能的化合物的角化不全抑制用皮肤外用剂以及毛孔缩小用皮肤外用剂。
背景技术
以往,人们由于毛孔明显而倍感烦恼,需要使用对其进行改善的皮肤外用剂。但是,有关毛孔明显的机理一直没有弄清楚,人们一般通过使用收敛化妆水或去角栓来应对。但是,收敛化妆水的目的在于收紧肌肤,通过利用醇使皮肤表面温度暂时下降,或者利用有机酸等使得蛋白质凝固。由于收敛化妆水是暂时性收紧肌肤,因此对皮肤的负荷增大,并且无法从根本上解决毛孔明显的问题,其效果不充分。
此外,去角栓属于将堵塞在毛孔内的角栓物理性去除的方法。使用这种方法时,物理力有时会对肌肤造成伤害、导致对肌肤产生副作用等问题。并且其效果也是暂时性的,角栓很快又会再生,或者有时会出现去除角栓后,毛孔反而变大的情况,其效果未必充分。
由以上情况可知,人们一直希望能够开发出对皮肤的负荷小、安全、且对毛孔明显症状的改善效果好的皮肤外用剂。
本发明正是鉴于以上情况而完成的,其目的在于阐明毛孔明显的机理,提供一种具有缩小毛孔机能的物质,进一步提供一种发挥上述机能、对毛孔明显症状进行改善的皮肤外用剂等的组合物。
发明内容
本发明的发明者们为解决上述课题,专心进行了研究。本发明的发明者们首先针对毛孔明显的机理进行了研究。
表皮角化细胞在基底层增殖,移动到上层成熟,变成角质层。当变成角质层时,细胞内的核消失,细胞扁平化。但是,有时表皮角化细胞会以细胞内有核的未成熟状态存在于角质层中,这就叫角化不全。当发生角化不全时,会引起角质层的复层剥离,由此导致毛孔变大。并且,毛孔明显不仅与其导管部相关,而且也归因于毛孔部(导管部的具有角栓的部位)周围的圆锥状结构。并且,毛孔部周围的圆锥状结构部位上皮肤状态恶化,引起角化不全,这就会导致毛孔扩大。
因此,关于毛孔明显的机理,很明显由皮脂引起的角化不全是其原因所在,抑制角化不全的物质对于缩小毛孔有效。即通过改善角化不全,能够起到令毛孔部周围的圆锥状结构缩小的作用,也即控制角化不全的话,就能实现缩小毛孔、改善毛孔明显症状的目的。
另一方面,本发明的发明者们发现皮脂中的刺激成分,即导致角化不全的油酸,具有使得表皮角化细胞等细胞兴奋(使钙浓度提高)的作用,并且发现兴奋性细胞受体的激动剂以及抑制性细胞受体的拮抗剂具有令角化不全恶化的作用。
由以上见解,本发明的发明者们发现在现阶段通过提供具有角化不全抑制机能、毛孔缩小机能的新的角化不全抑制剂以及毛孔缩小剂,可解决上述技术问题,并在此基础上进一步深入研究。
因此,本发明的发明者们在对具有抑制角化不全、缩小毛孔作用的化合物进行探索的过程中,发现兴奋性细胞受体的拮抗剂以及抑制性细胞受体的激动剂具有上述作用,从而完成了本发明。
上述物质具有抑制角化不全的作用这一点,就本发明的发明者们所知,尚未公知。并且,这些物质具有缩小毛孔部周围的圆锥状结构的作用这一点,就本发明的发明者们所知,也尚未公知。
即,本发明是一种含有兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的角化不全抑制剂。并且,本发明是一种含有兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的角化不全抑制用皮肤外用剂。
进一步,本发明还是一种含有兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的毛孔缩小剂。并且,本发明是含有兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的毛孔缩小用皮肤外用剂。
本发明中,用于上述角化不全抑制剂、角化不全抑制用皮肤外用剂、毛孔缩小剂以及毛孔缩小用皮肤外用剂的兴奋性细胞受体的拮抗剂以及抑制性细胞受体的激动剂,可举出以下优选使用的物质。即上述兴奋性细胞受体优选使用N-甲基-D-天冬氨酸受体等的谷氨酸受体或P2X受体等的ATP受体。
而且,上述N-甲基-D-天冬氨酸受体的拮抗剂优选使用地佐环平(dizocilpine)或D-谷氨酸。上述ATP受体的拮抗剂优选使用舒拉明、磷酸吡哆醛-6-偶氮苯基-2′,4′-二磺酸或三硝基苯基(trinitrophenyl)-ATP。
接下来,上述抑制性细胞受体优选使用Cl-通道内置型荷包牡丹碱敏感性受体等的γ-氨基丁酸受体或甘氨酸受体。
并且,上述Cl-通道内置型荷包牡丹碱敏感性受体的激动剂优选使用γ-氨基丁酸、蝇蕈醇、或异去甲槟榔次碱,上述甘氨酸受体的激动剂优选使用甘氨酸。
具体实施方式
以下就本发明的实施方式进行说明。
本发明中的上述角化不全抑制剂、毛孔缩小剂、角化不全抑制用皮肤外用剂以及毛孔缩小用皮肤外用剂中,使用了兴奋性细胞受体的拮抗剂以及抑制性细胞受体的激动剂。
本发明中所说的“兴奋性细胞受体”是指将存在于皮肤细胞,即存在于构成角质层、表皮、基底膜、真皮等的细胞,如存在于表皮角化细胞的表层的将细胞诱导至兴奋状态的兴奋性受体。该兴奋是由于在上述受体上结合了其激动剂,Ca2+或Na+离子流入细胞内而引起的。
作为这样的兴奋性细胞受体,例如谷氨酸受体、ATP受体、乙酰胆碱·烟酸样受体、5-羟色胺受体等目前在皮肤细胞中均可以发现,这些就是本发明的兴奋性细胞受体所指,但是本发明中所指的兴奋性细胞受体不仅限于这些,可认为其他受体以及将来能够发现的受体也在本发明的范围之内。
在本发明中,上述兴奋性细胞受体中优选谷氨酸受体以及ATP受体。进一步,谷氨酸受体中优选N-甲基-D-天冬氨酸受体(以下称NMDA受体)。并且,ATP受体优选P2X受体(变力性嘌呤受体(inotropicprinoreceptor))。
在本发明中,使用的是上述兴奋性细胞受体各自固有的拮抗剂。例如,NMDA受体的拮抗剂可以举出地佐环平(以下称之为MK-801)、D-谷氨酸、D-AP7、芋螺毒素(Conantokin T)、(R)-CPP等。此外,ATP受体的拮抗剂可举出舒拉明、磷酸吡哆醛-6-偶氮苯基-2′,4′-二磺酸(以下称PPADS)、三硝基苯基-ATP(以下称TNP-ATP)等。另外,乙酰胆碱·烟酸样受体的拮抗剂可举出苯醌铵、乱飞燕草碱(Condelphine)、α-海蜗牛毒素-E1(α-Conotoxin-E1)等。此外,5-羟色胺受体的拮抗剂可举出MDL-72222、Y-25130、甲氧氯普胺(Metoclopramide)等。
本发明中优选使用的兴奋性细胞受体的拮抗剂为NMDA受体的拮抗剂MK-801或D-谷氨酸、以及ATP受体的拮抗剂舒拉明、PPADS或TNP-ATP。在本发明中,不仅限于前述的拮抗剂或目前存在于皮肤细胞中的兴奋性细胞受体的拮抗剂,可以认为其他拮抗剂以及将来能够发现的拮抗剂也在本发明的范围之内。
本发明中的“抑制性细胞受体”是指存在于构成皮肤细胞的细胞的表层、将细胞由兴奋状态诱导至抑制状态的抑制性受体,其中,构成皮肤细胞的细胞是指构成角质层、表皮、基底膜、真皮等的细胞,如角化细胞。该抑制是由于在上述受体上结合了其激动剂,Cl-离子流入细胞内而引起的。
作为这样的抑制性细胞受体,例如γ-氨基丁酸受体(以下称GABA受体)、甘氨酸受体等目前在皮肤细胞中均可以发现,这些就是本发明的抑制性细胞受体所指,但是本发明中所指的抑制性细胞受体不仅限于这些,可认为其他受体以及将来能够发现的受体也在本发明的范围之内。
在本发明中,上述抑制性细胞受体中优选GABA受体、谷氨酸受体。进一步,GABA受体中优选Cl-通道内置型荷包牡丹碱敏感性受体(以下称A型-GABA受体)。
在本发明中,使用的是上述抑制性细胞受体各自固有的激动剂。例如A型-GABA受体的激动剂可举出γ-氨基丁酸(以下称GABA)、蝇覃醇、异去甲槟榔次碱、TACA、THIP等。此外,甘氨酸受体的激动剂可举出甘氨酸、β-丙氨酸、亚牛磺酸、丝氨酸、牛磺酸等。
在本发明中优选使用的抑制性细胞受体的激动剂为A型-GABA受体的激动剂GABA、蝇蕈醇、异去甲槟榔次碱、以及谷氨酸受体的激动剂谷氨酸。在本发明中,不只限于前述的激动剂或目前存在于皮肤细胞中的抑制性细胞受体的激动剂,可以认为其他激动剂以及将来能够发现的激动剂也在本发明的范围之内。
本发明涉及的兴奋性细胞受体的拮抗剂以及抑制性细胞受体的激动剂,如后文所证实的那样,具有优良的抑制角化不全的机能、毛孔缩小机能。因此,作为角化不全抑制剂、毛孔缩小剂有用。
进一步,含有上述本发明的兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的组合物,被发现具有前述本发明的兴奋性细胞受体的拮抗剂以及抑制性细胞受体的激动剂所具有的角化不全抑制机能、毛孔缩小机能,因此能够应用于角化不全抑制用皮肤外用剂、毛孔缩小用皮肤外用剂等的组合物(以下称外用组合物)。
即,本发明中的外用组合物,可有效地用作以毛孔缩小剂为代表的、用于改善鼻、颊等的毛孔明显症状的脸用化妆料、或对腿等进行脱毛处理后的毛孔明显症状进行改善的体用皮肤外用剂等适用于表皮的药品,准药、化妆品等,尤其适宜作为化妆品使用,对维持肌肤的健康状态有所贡献。
兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂与本发明涉及的外用组合物混合时,可使用由上述化合物中任意选择的1种或2种以上。此外,本发明中的兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的含量,优选占上述外用组合物总量的0.001~20质量%,进一步优选占0.01~10.0质量%,特别优选占0.1~5.0质量%。其含量不到0.001质量%的话,本发明的效果不能得到充分发挥,另一方面含量超出20.0质量%的话,难以形成制剂,因此,不甚优选。此外,即便混合量超过10.0质量%,也看不到有很大的效果提升。
本发明中的上述外用组合物,按照通常方法制造即可,此外构成外用组合物的成分,可以利用前述本发明的兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂进行单独调制,也可以根据需要适当混合一般用于化妆品或药品等皮肤外用剂的成分,如油分、表面活性剂、粉末、着色剂、水、保湿剂、增粘剂、醇类、各种皮肤营养剂、抗氧化剂、紫外线吸收剂、香料、防腐剂等。
此外,还可适当混合乙二胺四乙酸二钠、乙二胺四乙酸三钠、柠檬酸钠、多磷酸钠、偏磷酸钠、葡糖酸等的金属封闭剂;咖啡因、单宁、维拉帕米、及它们的衍生物;甘草提取物、光甘草定(glabridin)、火棘果实的热水提取物、各种生药、生育酚醋酸酯、甘草酸及它们的衍生物或盐等的药剂、维生素C、抗坏血酸磷酸镁、抗坏血酸糖苷、熊果苷、曲酸等的美白剂;葡萄糖、果糖、甘露糖、蔗糖、海藻糖等糖类;视黄醇、视黄酸、视黄醇醋酸酯、视黄醇棕榈酸酯等维生素A类等。
本发明中上述组合物所用的剂型广泛,可采用水溶液类、可溶液化类、乳化类、粉末类、油液类、凝胶类、软膏类、气雾剂类、水-油2相类、水-油-粉末3相类等剂型。即,如果是基础化妆品的话,可以以上述多种剂型广泛用于洁面剂、化妆水、乳液、面霜、凝胶(gel)、精华液(美容液)、膜(pack)、面膜(mask)等形态。此外,如果是化妆用化妆品的话,可广泛用于粉底霜等,作为盥洗用品可广泛用于沐浴皂、肥皂等形态。还有,如果用作准药的话,可广泛使用于各种软膏剂等的形态。并且,本发明中的外用组合物所能采用的形态并不限于这些剂型及形态。
【实施例】
以下举出实施例,对本发明进行具体的说明。关于混合量的记载,如无特殊说明,均指质量%。
【关于油酸引起的细胞兴奋化作用的试验】
将表皮角化细胞置于适当的培养基、如KGM培养基上,按照通常方法进行培养。在进行钙离子测定的前一天,将该培养细胞播种到盖玻片上进行培养。次日,在上述培养细胞中以约2μM的量,添加适当的缓冲溶液、如BSS(Balanced Salt Solution)以及钙敏感性荧光色素、fura2-AM,在适当的条件下进行培养(如,37℃下30分钟),将该荧光色素引入到细胞内。引入后,加入新鲜的上述缓冲溶液(BSS)。之后,添加溶解了供试品(油酸)的同一缓冲溶液(BSS),然后对细胞内的钙离子浓度进行测定。并且,作为对照,只添加上述缓冲溶液(BSS)后,进行了同样的测定。结果如表1所示。此外,钙浓度为依照通常方法,使用340nm的荧光值除以360nm的荧光值后得到的值。
表1
样品浓度 | 细胞内钙浓度变化(荧光值的比的变化)平均±SE |
对照缓冲溶液 | 0.051±0.007 |
油酸(50μM) | 0.304±0.038 |
由表1的结果可以发现,皮脂中的刺激成分油酸具有使得表皮角化细胞等的细胞兴奋(使得钙浓度上升)的作用。由此可知,通过兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂来对皮脂引起的细胞兴奋进行抑制,是用于抑制角化不全或使得毛孔缩小的有效方法。
【样品的调制】
制成GABA、甘氨酸、D-谷氨酸、L-谷氨酸各为3%的水溶液,根据需要将其pH值调整为中性。此外,制成GABA、甲溴荷包牡丹碱(bicuculline methobromide)(A型-GABA受体拮抗剂)、MK-801、蝇蕈醇、异去甲槟榔次碱、ATP、舒拉明、PPADS、TNP-ATP的10mM水溶液。
【关于角化不全抑制作用的试验】
往无毛小鼠背部涂覆3%或30%油酸(溶剂:乙醇)100μL。之后涂覆样品溶液或对照水溶液100μL。将这一操作重复3天,利用胶带将其背部的角质层剥落。使用苏木精将核染色,在显微镜下对此时的角质层进行观察,观察有核角质层细胞的数目,并按照1~4的4个阶段进行了评价。涂覆30%油酸时的试验结果如表2所示,涂覆3%油酸试验的结果如表3所示。另外,涂覆3%油酸时的评价基准和涂覆30%油酸时的评价基准不同,各自进行相对评价。
表2 涂覆30%油酸的试验
样品(各3%) | 角化不全度(4只平均) |
对照水溶液 | 2.5 |
GABA | 1.5 |
甘氨酸 | 1.3 |
D-谷氨酸 | 2.0 |
L-谷氨酸 | 3.0 |
表3 涂覆3%油酸的试验
样品(各10mM) | 角化不全度(4只平均) |
对照水溶液 | 2.0 |
GABA | 1.5 |
GABA+甲溴荷包牡丹碱 | 2.5 |
MK-801 | 1.0 |
蝇蕈醇 | 1.3 |
异去甲槟榔次碱 | 1.3 |
ATP | 2.3 |
舒拉明 | 1.5 |
PPADS | 1.8 |
TNP-ATP | 1.5 |
由2、3的结果所示,作为兴奋性细胞受体的谷氨酸受体(NMDA受体)的激动剂L-谷氨酸会使得油酸引起的角化不全恶化,而谷氨酸受体(NMDA受体)的拮抗剂MK-801以及D-谷氨酸则能够改善油酸引起的角化不全。
并且,作为兴奋性细胞受体的ATP受体(P2X受体)的激动剂ATP会使得油酸引起的角化不全恶化,而ATP受体(P2X受体)的拮抗剂舒拉明、PPADS以及TNP-ATP则能够改善油酸引起的角化不全。
进一步,作为抑制性细胞受体的GABA受体(A型-GABA受体)的激动剂GABA、蝇蕈醇、以及异去甲槟榔次碱能够改善油酸引起的角化不全,而GABA受体(A型-GABA受体)的拮抗剂甲溴荷包牡丹碱则阻碍了GABA针对油酸引起的角化不全的抑制作用。
此外,作为抑制性细胞受体的甘氨酸受体的激动剂甘氨酸,改善了油酸引起的角化不全。
如上所示,可明确得知兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂具有抑制油酸引起的角化不全的作用。
【关于毛孔缩小作用的试验】
对健康男性的脸部进行试验,将样品溶液涂覆到上述健康男性脸部,持续1个月,每天涂覆2次。样品溶液(甘氨酸、GABA、D-谷氨酸)各为3%。试验完成前后采集复制物(replica),在3维激光扫描显微镜下对同一部位的毛孔形状变化进行观察。按照视觉判断分1~13共13个阶段对毛孔的大小进行评价。计算出试验前后的评价分数的差,作为对各药剂的评价。其结果如表4所示。
表4
样品 | 毛孔复制物判定(n=5的平均) |
甘氨酸 | -1.2 |
GABA | -1.0 |
D-谷氨酸 | -0.4 |
由表4的结果可知,作为兴奋性细胞受体的拮抗剂或抑制性细胞受体的激动剂的甘氨酸、GABA、D-谷氨酸具有优良的毛孔缩小效果。
以下,以实施例的形式将本发明的外用组合物表示如下。另外,实施例中的每一种类型的组合物也都具有作为角化不全抑制用皮肤外用剂、毛孔缩小用皮肤外用剂使用的优良效果。
【实施例1雪花膏】
(处方) 混合量(质量%)
硬脂酸 5.0
硬脂醇 4.0
肉豆蔻酸异丙酯 18.0
单硬脂酸甘油酯 3.0
丙二醇 10.0
甘氨酸 0.5
氢氧化钾 0.3
亚硫酸氢钠 0.01
防腐剂 适量
香料 适量
离子交换水 剩余
(制法)
往离子交换水中加入丙二醇、甘氨酸以及氢氧化钾,溶解,加热,保持在70℃(水相)。混合其他成分,加热溶解,保持在70℃(油相)。往水相中徐徐加入油相,待全部加入后保持该温度一段时间,并使其分散。最后,使用均质混合器使其均匀乳化,边充分搅拌使其冷却至30℃。
【实施例2雪花膏】
(处方) 混合量(质量%)
固体石蜡 5.0
蜂蜡 10.0
凡士林 15.0
液体石蜡 41.0
单硬脂酸甘油酯 2.0
聚氧乙烯(20摩尔)脱水山梨糖醇单月桂酸酯 2.0
肥皂粉末 0.1
硼砂 0.2
PPADS·4钠盐 0.05
亚硫酸氢钠 0.03
对羟基苯甲酸乙酯 0.3
香料 适量
离子交换水 剩余
(制法)
往离子交换水中加入肥皂粉末、硼砂以及PPADS·4钠盐,加热、溶解,保持在70℃(水相)。混合其他成分,加热、溶解,保持在70℃(油相)。边搅拌油相,边将油相徐徐加入到水相中,发生反应。反应结束后,使用均质混合器使其均匀乳化,乳化后充分搅拌使其冷却至30℃。
【实施例3乳液】
(处方) 混合量(质量%)
硬脂酸 2.5
十六醇 1.5
凡士林 5.0
液体石蜡 10.0
聚氧乙烯(10摩尔)单油酸酯 2.0
聚乙二醇1500 3.0
三乙醇胺 1.0
羧基乙烯基聚合物 0.05
(商品名:carbopol 941、B.F.Goodrich Chemical company)
GABA 0.5
氢氧化钾 0.4
亚硫酸氢钠 0.01
对羟基苯甲酸乙酯 0.3
香料 适量
离子交换水 剩余
(制法)
在少量的离子交换水中溶解羧基乙烯基聚合物、GABA以及氢氧化钾(A相)。往剩余的离子交换水中加入聚乙二醇1500及三乙醇胺,加热、溶解,保持在70℃(水相)。将其他成分混合,加热、溶解,保持在70℃(油相)。往水相中加入油相,进行预乳化,加入A相,使用均质混合器使其均匀乳化,乳化后边充分搅拌,边使其冷却至30℃。
【实施例4凝胶】
(处方) 混合量(质量%)
95%乙醇 10.0
一缩二丙二醇 15.0
聚氧乙烯(50摩尔)油醇醚 2.0
羧基乙烯基聚合物 1.0
(商品名:carbopol 940,B.F.Goodrich Chemical company)
氢氧化钠 1.0
L-精氨酸 0.1
甘氨酸 5.0
二吗啉代哒嗪酮
(dimorpholinopyridazinon) 0.05
乙二胺四乙酸·3钠·2水 0.05
对羟基苯甲酸甲酯 0.2
香料 适量
离子交换水 剩余
(制法)
将carbopol 940均匀溶解在离子交换水中,另一方面,将聚氧乙烯(50摩尔)油醇醚溶解在95%乙醇中,添加到水相中。接着,在加入其他成分后,使用氢氧化钠、L-精氨酸中和,增粘。
【实施例5美容液】
(处方) 混合量(质量%)
(A相)
乙醇(95%) 10.0
聚氧乙烯(20摩尔)辛基十二醇 1.0
泛酸基乙基醚(pantotenyl ethyl ether) 0.1
对羟基苯甲酸甲酯 0.15
(B相)
氢氧化钾 0.1
(C相)
甘油 5.0
一缩二丙二醇 10.0
MK-801 0.03
羧基乙烯基聚合物 0.2
(商品名:carbopol 940,B.F.Goodrich Chemical company)
纯水 剩余
(制法)
将A相、C相分别均匀溶解,把A相加入到C相中,使其溶解。接着,加入B相后进行填充。
【实施例6化妆水】
(处方) 混合量(质量%)
甘油 5.0
1,3-丁二醇 3.0
一缩二丙二醇 2.0
琥珀酸钠 0.1
琥珀酸 0.07
舒拉明 0.01
乙醇 5.0
对羟基苯甲酸甲酯 0.15
香料 适量
乙二胺四乙酸·3钠·2水 0.1
纯水 剩余
(制法)
在乙醇中加入对羟基苯甲酸乙酯和香料,溶解(醇相)。往纯水中加入该醇相以及其他成分,溶解,填充。
【实施例7化妆水】
(处方) 混合量(质量%)
甘油 2.0
一缩二丙二醇 5.0
柠檬酸钠 0.08
柠檬酸 0.02
D-谷氨酸 0.5
KOH 0.01
日本鹿蹄草提取液(乙醇提取) 0.05
木通提取液(1,3-丁二醇提取) 0.05
乙醇 2.0
苯氧基乙醇 0.05
聚氧乙烯聚氧丙烯癸基十四烷基醚 0.02
香料 适量
乙二胺四乙酸·3钠·2水 0.1
纯水 剩余
(制法)
在纯水中加入其他成分,溶解,填充。
【实施例8化妆水(微乳液)】
(处方) 混合量(质量%)
1,3-丁二醇 6.0
甘油 5.0
聚乙二醇4000 3.0
橄榄油 0.5
聚氧乙烯(20摩尔)脱水山梨糖醇单硬脂酸酯 1.5
聚氧乙烯(5摩尔)油基单醇醚 0.3
乙醇 1.0
蝇蕈醇 0.05
柠檬酸 0.07
柠檬酸钠 0.03
对羟基苯甲酸甲酯 0.15
香料 适量
纯水 剩余
(制法)
在纯水中加入1,3-丁二醇、甘油、聚乙二醇4000、蝇蕈醇、柠檬酸、柠檬酸钠,溶解(水相)。另一方面,在乙醇中加入橄榄油、聚氧乙烯(20摩尔)脱水山梨糖醇单硬脂酸酯、聚氧乙烯(5摩尔)油基单醇醚、对羟基苯甲酸甲酯、香料,溶解(醇相)。将该醇相加入到前述水相中,调整微乳液,填充。
【实施例9粉末化妆水】
(处方) 混合量(质量%)
乙醇 15.0
甘油 2.0
1,3-丁二醇 2.0
TNP-ATP 0.01
L-精氨酸 0.1
氧化铁 0.15
氧化锌 0.5
高岭土 2.0
HEDTA3Na 0.2
薄荷醇 0.2
香料 适量
纯水 剩余
(制法)
往纯水中加入甘油、1,3-丁二醇、TNP-ATP、L-精氨酸,溶解(水相)。另一方面,在乙醇中加入薄荷醇、香料,溶解(醇相)。将水相添加到该醇相中,溶解,添加氧化铁、氧化锌、高岭土。使用均质混合器对其进行处理后,填充到容器中。
【实施例10乳化型粉底】
(处方) 混合量(质量%)
(粉体部分)
二氧化钛 10.3
绢云母 5.4
高岭土 3.0
黄色氧化铁 0.8
氧化铁红 0.3
黑色氧化铁 0.2
(油相)
十甲基环戊硅氧烷 11.5
液体石蜡 4.5
聚氧乙烯改性二甲基聚硅氧烷 4.0
(水相)
纯水剩余
1,3-丁二醇 4.5
异去甲槟榔次碱 0.01
脱水山梨糖醇倍半油酸酯 3.0
防腐剂 适量
香料 适量
(制法)
将水相加热搅拌,添加充分混合粉碎后的粉状部分,使用均质混合器进行处理。接着加入加热混合后得到油相,使用均质混合器处理后,边搅拌,边添加香料,冷却至室温。
工业实用性
如以上说明所述,根据本发明,兴奋性细胞受体的拮抗剂以及抑制性细胞受体的激动剂,具备用作角化不全抑制剂、毛孔缩小剂的机能,其通过对尤其易受毛孔部周围的皮脂影响的部位的皮脂成分中的刺激成分所引起的角化不全进行抑制,能够达到防止毛孔部周围的圆锥化,抑制圆锥状结构明显症状,缩小毛孔,维持毛孔不明显的健康肌肤状态等优良的效果,通过含有上述化合物作为有效成分,能够得到优良的角化不全抑制用皮肤外用剂以及毛孔缩小用皮肤外用剂。
Claims (2)
1.N-甲基-D-天冬氨酸受体的拮抗剂在制备角化不全抑制剂中的应用,其中,所述N-甲基-D-天冬氨酸受体的拮抗剂为D-谷氨酸。
2.权利要求1所述的应用,角化不全抑制剂为毛孔缩小剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002153457A JP4473491B2 (ja) | 2002-05-28 | 2002-05-28 | 毛穴縮小剤 |
JP2002-153457 | 2002-05-28 | ||
JP2002153457 | 2002-05-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038123096A Division CN1655813A (zh) | 2002-05-28 | 2003-05-23 | 角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101675922A true CN101675922A (zh) | 2010-03-24 |
CN101675922B CN101675922B (zh) | 2012-01-11 |
Family
ID=29561299
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038123096A Pending CN1655813A (zh) | 2002-05-28 | 2003-05-23 | 角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 |
CN2009101674956A Expired - Lifetime CN101675922B (zh) | 2002-05-28 | 2003-05-23 | 角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA038123096A Pending CN1655813A (zh) | 2002-05-28 | 2003-05-23 | 角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050152930A1 (zh) |
EP (1) | EP1550459B1 (zh) |
JP (1) | JP4473491B2 (zh) |
KR (1) | KR101012679B1 (zh) |
CN (2) | CN1655813A (zh) |
WO (1) | WO2003099327A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2491980A2 (en) * | 2003-11-27 | 2012-08-29 | Shiseido Company Limited | Parakeratosis inhibitor and skin preparation for external use |
JP5241058B2 (ja) * | 2003-11-27 | 2013-07-17 | 株式会社 資生堂 | 不全角化抑制剤及び毛穴縮小剤 |
JP4585342B2 (ja) * | 2005-03-18 | 2010-11-24 | 株式会社資生堂 | 不全角化を抑制する物質のスクリーニング方法、同方法によりスクリーニングされた物質及び不全角化を抑制する方法 |
JP4865251B2 (ja) * | 2005-05-09 | 2012-02-01 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤及び皮膚外用組成物 |
JP4838537B2 (ja) * | 2005-05-25 | 2011-12-14 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤又は肌荒れ防止・改善剤及び皮膚外用組成物 |
EP1800672A1 (de) * | 2005-12-23 | 2007-06-27 | Dr. August Wolff GmbH & Co. | Pharmazeutische Zusammensetzung und deren Verwendung zur Behandlung von Dermatosen |
JP4887050B2 (ja) * | 2006-02-01 | 2012-02-29 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤 |
JP4704419B2 (ja) * | 2007-12-27 | 2011-06-15 | 学校法人順天堂 | 皮膚角化促進剤 |
JP5558728B2 (ja) * | 2008-03-12 | 2014-07-23 | 株式会社 資生堂 | 皮膚外用組成物 |
EP2255780A1 (en) * | 2008-03-12 | 2010-12-01 | Shiseido Company, Ltd. | Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same |
WO2012133408A1 (ja) * | 2011-03-28 | 2012-10-04 | 株式会社 資生堂 | フィルム状外用剤組成物 |
JP5254417B2 (ja) * | 2011-10-07 | 2013-08-07 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤及び肌荒れ防止・改善剤 |
JP2014185141A (ja) * | 2013-02-22 | 2014-10-02 | Mikimoto Pharmaceut Co Ltd | インボルクリン産生促進剤、皮膚角化促進剤 |
EP3840646B1 (en) | 2018-08-21 | 2024-07-03 | The Procter & Gamble Company | Methods for identifying pore color |
KR20220156034A (ko) | 2020-05-08 | 2022-11-24 | 더 프록터 앤드 갬블 캄파니 | 수지상 기공을 식별하는 방법 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57156329A (en) * | 1981-03-19 | 1982-09-27 | Shiseido Co Ltd | Solubilization of zinc oxide |
JPS57158724A (en) * | 1981-03-26 | 1982-09-30 | Shiseido Co Ltd | Antimicrobial composition |
JPS59216812A (ja) * | 1983-05-26 | 1984-12-06 | Dowa Yakushiyou Kk | 頭髪育毛料 |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
JP3436544B2 (ja) * | 1991-11-25 | 2003-08-11 | 株式会社創研 | 皮膚治療剤 |
UA10208A (uk) * | 1994-08-03 | 1996-12-25 | Жанна Прокопівна Гудзенко | Дерматологічний косметичний засіб |
FR2728166A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
US6380255B1 (en) * | 1995-06-07 | 2002-04-30 | Karo Bio Ab | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
FR2735367B1 (fr) * | 1995-06-19 | 1997-07-18 | Cird Galderma | Utilisation de ligands specifiques des recepteurs rxrs |
FR2738745B1 (fr) * | 1995-09-15 | 1997-10-24 | Cird Galderma | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations |
US6197830B1 (en) * | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
JPH09255547A (ja) * | 1996-03-22 | 1997-09-30 | Kao Corp | 皮膚外用剤 |
ATE236654T1 (de) * | 1996-08-28 | 2003-04-15 | Inst Nat Sante Rech Med | Therapeutische kombinationen von rar-antagonisten und rxr-agonisten |
FR2753627B1 (fr) * | 1996-09-20 | 2003-02-21 | Galderma Rech Dermatologique | Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation |
CN1054505C (zh) * | 1996-12-11 | 2000-07-19 | 林镇才 | 一种活性成份的化妆品添加剂 |
JP3389071B2 (ja) * | 1997-09-04 | 2003-03-24 | 花王株式会社 | 化粧料 |
JPH1160469A (ja) * | 1997-08-22 | 1999-03-02 | Kanebo Ltd | 浴用組成物 |
US5958976A (en) * | 1997-09-19 | 1999-09-28 | E-L Management Corp. | Composition and method for reducing stinging in skin |
JP3636271B2 (ja) * | 1997-11-26 | 2005-04-06 | 株式会社ノエビア | 皮膚外用剤 |
AU1072701A (en) * | 1999-10-04 | 2001-05-10 | Chiron Corporation | Cd40 antagonist for treating psoriasis |
WO2002011677A2 (en) * | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
JP2002316929A (ja) * | 2001-04-18 | 2002-10-31 | Japan Science & Technology Corp | L−セリン又はグリシンからなる抗アポトーシス剤 |
WO2002096360A2 (en) * | 2001-05-25 | 2002-12-05 | Ceremedix, Inc. | Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
WO2003053466A1 (fr) * | 2001-12-13 | 2003-07-03 | Shiseido Company, Ltd. | Accelerateurs de reparation de la fonction barriere de la peau |
-
2002
- 2002-05-28 JP JP2002153457A patent/JP4473491B2/ja not_active Expired - Fee Related
-
2003
- 2003-05-23 WO PCT/JP2003/006467 patent/WO2003099327A1/ja active Application Filing
- 2003-05-23 EP EP03730607A patent/EP1550459B1/en not_active Expired - Lifetime
- 2003-05-23 US US10/515,219 patent/US20050152930A1/en not_active Abandoned
- 2003-05-23 KR KR1020047018694A patent/KR101012679B1/ko active IP Right Grant
- 2003-05-23 CN CNA038123096A patent/CN1655813A/zh active Pending
- 2003-05-23 CN CN2009101674956A patent/CN101675922B/zh not_active Expired - Lifetime
-
2008
- 2008-01-24 US US12/010,373 patent/US20080269304A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2003342195A (ja) | 2003-12-03 |
EP1550459B1 (en) | 2013-01-02 |
CN101675922B (zh) | 2012-01-11 |
EP1550459A4 (en) | 2008-05-21 |
KR20050014825A (ko) | 2005-02-07 |
CN1655813A (zh) | 2005-08-17 |
EP1550459A1 (en) | 2005-07-06 |
JP4473491B2 (ja) | 2010-06-02 |
WO2003099327A1 (fr) | 2003-12-04 |
US20080269304A1 (en) | 2008-10-30 |
US20050152930A1 (en) | 2005-07-14 |
KR101012679B1 (ko) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101675922B (zh) | 角化不全抑制剂、毛孔缩小剂以及皮肤外用剂 | |
CN101227885A (zh) | 皱纹防止·改善剂 | |
JP2005508936A (ja) | 抗刺激性酒さ治療 | |
US11478522B2 (en) | Synergistic herbal compositions with prebiotic properties for treatment of acne | |
EP2316411A2 (en) | Compositions comprising a skin-lightening resorcinol and a skin darkening agent | |
CN109481370A (zh) | 一种舒缓抗过敏抗刺激护肤组合物及其制备方法和应用 | |
JP2001288066A (ja) | 皮膚バリアー機能改善剤 | |
KR101165288B1 (ko) | 부전각화 억제제 | |
KR20030086270A (ko) | 피부의 탄력성 저하를 억제하는 방법 | |
US20210369583A1 (en) | Compositions for providing skin care benefits and methods of use | |
WO1998052516A1 (en) | Scalp care compositions | |
JP3140357B2 (ja) | 美白用皮膚外用剤 | |
JP2003252718A (ja) | 生体内ジヒドロキシインドール化合物の重合抑制剤 | |
JPS6322510A (ja) | 皮膚外用剤 | |
JPH0930945A (ja) | 皮膚外用剤 | |
CN113197788A (zh) | 一种均匀肤色美白组合物及护肤化妆品 | |
WO2016110872A1 (en) | Foot care compositions | |
JPH0920635A (ja) | 美白用皮膚外用剤 | |
JPH0930948A (ja) | 美白用皮膚外用剤 | |
JP3527406B2 (ja) | 美白用皮膚外用剤 | |
KR100331979B1 (ko) | 피부외용제 | |
JPH11269033A (ja) | 皮膚プレトリートメント剤 | |
CN1272360A (zh) | 化妆品 | |
JP2004026657A (ja) | 美白用の化粧料 | |
HRP20220587A1 (hr) | Kozmetička formulacija, postupak njezine priprave i upotreba |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20120111 |